-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, a domestic multi-center team published a real-world study in the journal Liver Cancer, mainly to explore the treatment of unresectable advanced liver disease with lenvatinib combined with or without drug-eluting microspheres transarterial chemoembolization (DEB-TACE).
Recently, a domestic multi-center team published a real-world study in the journal Liver Cancer, mainly to explore the treatment of unresectable advanced liver disease with lenvatinib combined with or without drug-eluting microspheres transarterial chemoembolization (DEB-TACE).
This retrospective analysis of 142 patients who received lenvatinib (LEN) combined with DEB-TACE and 69 patients who received only lenvatinib first-line therapy at 15 centers in China from November 2018 to November 2019
This retrospective analysis of 142 patients who received lenvatinib (LEN) combined with DEB-TACE and 69 patients who received only lenvatinib first-line therapy at 15 centers in China from November 2018 to November 2019
The median follow-up time was 13.
The median follow-up time was 13.
After propensity-matched analysis, the combination group significantly prolonged patients' median OS compared with the single-agent group (13.
After propensity-matched analysis, the combination group significantly prolonged patients' median OS compared with the single-agent group (13.
The incidences of CR, PR, SD and PD in the LEN + DEB-TACE combination group were 4.
After multivariate Cox regression analysis, tumor number (HR=1.
After multivariate Cox regression analysis, tumor number (HR=1.
In both groups of patients, the main AEs were increased aspartate aminotransferase (AST) (54.
In both groups of patients, the main AEs were increased aspartate aminotransferase (AST) (54.
In conclusion, the study showed that lenvatinib combined with drug-eluting microspheres for transarterial chemoembolization in the treatment of unresectable advanced hepatocellular carcinoma has significant efficacy and good safety
In conclusion, the study showed that lenvatinib combined with drug-eluting microspheres for transarterial chemoembolization in the treatment of unresectable advanced hepatocellular carcinoma has significant efficacy and good safety
Original source:
Xia D, Bai W, Wang E, et al.
Xia D, Bai W, Wang E, et al.
Lenvatinib with or without concurrent drug-eluting beads transarterial chemoembolization in patients with unresectable, advanced hepatocellular carcinoma: A real-world, multicenter, retrospective study.
Liver Cancer , DOI: 10.
1159/000523849 .
Published online: March 9, 2022Leave
a Comment here
